Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Posted: October 7, 2024 at 2:37 am
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Compensation Committee of its Board of Directors (Compensation Committee) granted Dipesh Bhatt, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 1,110 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of September 30, 2024. The stock option has an exercise price of $10.75 per share, which is equal to the closing price of Cidara’s common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.
The rest is here:
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Posted in Global News Feed
Comments Off on Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
Posted: October 7, 2024 at 2:37 am
-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3K?), initially in breast cancer
Continue reading here:
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
Posted in Global News Feed
Comments Off on OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
Posted: October 7, 2024 at 2:37 am
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.
See the original post here:
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
Posted in Global News Feed
Comments Off on Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
Posted: October 7, 2024 at 2:37 am
REGULATED INFORMATION
The rest is here:
BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
Posted in Global News Feed
Comments Off on BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
Posted: October 7, 2024 at 2:37 am
Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.
More:
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
Posted in Global News Feed
Comments Off on Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies
Posted: October 7, 2024 at 2:37 am
PRESS RELEASE
Here is the original post:
IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies
Posted in Global News Feed
Comments Off on IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in…
Posted: October 7, 2024 at 2:37 am
London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca’s Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma has delivered positive results. The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction1 in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol.
Go here to see the original:
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in...
Posted in Global News Feed
Comments Off on Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca’s inhaled anti-inflammatory medication Airsupra in…
Bavarian Nordic Upgrades its Financial Guidance for 2024
Posted: September 27, 2024 at 2:51 am
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024.
More here:
Bavarian Nordic Upgrades its Financial Guidance for 2024
Posted in Global News Feed
Comments Off on Bavarian Nordic Upgrades its Financial Guidance for 2024
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
Posted: September 27, 2024 at 2:51 am
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak.
Read the original post:
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
Posted in Global News Feed
Comments Off on Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
Posted: September 27, 2024 at 2:51 am
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
More here:
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
Posted in Global News Feed
Comments Off on OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update